Metabolic syndrome. Obesity, unspecified
Conditions
Interventions
Intervention 1: intervention group consume Purslane extract capsules. Two capsules 500 mg , one 30 minutes before breakfast and another 30 minutes before dinner. Intervention 2: control group consume
Treatment - Drugs
Placebo
intervention group consume Purslane extract capsules. Two capsules 500 mg , one 30 minutes before breakfast and another 30 minutes before dinner.
control group consume placebo capsule for 2 months. 1 capsule 30 minutes before breakfast and 1 capsule 30 minutes before dinner. Placebo was made ??of calcium phosphate
Sponsors
Vice chancellor for research,Isfahan University of Medical Science
Isfahan University of Medical Sciences, School of Nutrition- School Nutrition Research Center
Eligibility
Sex/Gender
Male
Age
27 Years to 59 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: persons suffering from obesity as defined by the IDF (WC= 102 in men) and have 2 signs of the 4 following symptoms, the metabolic syndrome was diagnosed. In this study, the characteristics of metabolic syndrome will be considered, if the criteria were the terms of this syndrome (having 2 of the first 4), other criteria will be checked: 1-high blood pressure (systolic>130mhg and diastolic>85mmhg); 2-fasting blood glucose>100mg/dl; 3-TG>150mg/dl; 4-HDL<40mg/dl; -gender: male; no history of cancer, kidney, thyroid, diabetes, and anemia; lack of use of alcohol and drugs; no smoking history or drug allergy; no special diet; no change in medication in the last three months; lack of drugs that control blood sugar, lipid and blood pressure; no taking medications affecting inflammation, such as corticosteroids. Exclusion criteria: during the study , patients who lose their inclusion criteria, including smoking; suffering from diseases such as heart problems , kidney , thyroid and digestive disorders and lack of cooperation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum high sensitive-C Reactive Protein (hs-CRP) levels. Timepoint: In the first of intervention and end of 8th week. Method of measurement: mg/l-imonotorbidometry.;NON-HDL CHOL. Timepoint: In the first of intervention and end of 8th week. Method of measurement: Calculation method.;Waist circumference. Timepoint: In the first of intervention and end of 8th week. Method of measurement: meter, centimeter.;Weight. Timepoint: In the first of intervention and end of 8th week. Method of measurement: scale, kilogram.;Body mass index. Timepoint: In the first of intervention and end of 8th week. Method of measurement: kg/m2, Weight/Height square.;Diastolic blood pressure. Timepoint: In the first of intervention and end of 8th week. Method of measurement: mmHg, Mercurial sphygmomanometer.;Systolic blood pressure. Timepoint: In the first of intervention and end of 8th week. Method of measurement: mmHg, Mercurial sphygmomanometer.;Fasting blood sugar. Timepoint: In the first of intervention and end of 8th week. Method of measurement: Enzymatic, mg/dL.;Serum total cholesterol levels. Timepoint: In the first of intervention and end of 8th week. Method of measurement: Enzymatic, mg/dL.;Serum High-Density Lipoprotein cholesterol (HDL-c) levels. Timepoint: In the first of intervention and end of 8th week. Method of measurement: Enzymatic, mg/dL.;Serum Low-Density Lipoprotein cholesterol (LDL-c) levels. Timepoint: In the first of intervention and end of 8th week. Method of measurement: Calculation method.;Fibrinogen. Timepoint: In the first of intervention and end of 8th week. Method of measurement: Clauss method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarjan Badakhanian
Isfahan University of Medical Sciences
Outcome results
None listed